CIVICA INC

Programs

1. Generic drug distributiondevelop an open and growing network of hospitals to expand the reach of civica's mission and its benefits to both members and non-members. Alleviate shortages of essential drug products and stabilize pricing by securing availability from existing manufacturers for the benefit of patients served by these members and non-member customers. Civica's major accomplishments to date include the following:(1) continued customer growth with 85 million patients served to date. New customers enrolled include nationwide non-member 340b hospitals that serve a disproportionate population of high-need patients, veterans affairs hospitals, and the department of defense. (2) continued launch of essential medicines deemed in short supply per the fda or ashp drug shortages lists.(3) established and maintained approximately 6 months of finished goods inventory to buffer any supply chain shocks typically experienced in the industry for essential sterile injectable medicines. (4) single transparent affordable pricing to all members and non-members regardless of membership status, size of the hospital, volume of drugs purchased from civica or relationship longevity with civica.

   $36,894,776 spent$31,500,392 earned by the program
   42% of program spending

2. Fill - finish facilitythe covid-19 pandemic, which resulted in a spike in demand for medications in hospitals managing significant patient surges, brought to light the dependence of the united states on foreign manufacturers of generic, essential, life-saving medications; especially sterile injectables. In an effort to on-shore end-to-end manufacturing of such sterile injectables, and as a national security measure, biomedical advanced research and development authority ("barda"), a u.s. Department of health and human services ("hhs") government office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear threats, as well as pandemic influenza and emerging diseases, awarded contract no. 75a50120c00092 ("prime contract") to phlow corp., ("phlow") to create end-to-end manufacturing in the united states. Phlow is a delaware public benefit corporation engaged in the business of the research, development, and commercialization of pharmaceutical products. Phlow subcontracted certain of its obligations under the prime contract to civica whereby civica will qualify, design,…

   $48,851,416 spent
   56% of program spending

3. Out-patient serviceson or about january 23, 2020, civica announced an arrangement with the blue cross blue shield association ("bcbsa") and a number of independent blue cross and blue shield companies ("bcbss; with bcbsa, the "blues"). The arrangement involved the creation of a new business entity, civicascript, dedicated to lowering the cost of select outpatient generic medications in response to the impact of high drug costs on the health of americans and the overall affordability of health care by developing and manufacturing generic outpatient medications. In furtherance of the arrangement, on or about january 27, 2020, civica caused civicascript to be organized as a delaware limited liability company to promote public benefits, including promotion of availability of affordable outpatient generic drugs. Civicascript, a statutory public benefit llc under delaware law , is treated as a corporation for u.s federal tax purposes. However, civicascript has applied for tax-exempt status as a public charity. If approved, the effective date of exemption would be september 1, 2023.based on market and other research by civicascript, as approved by its board, civicascript is currently in…

   $1,210,295 spent$1,210,295 earned by the program
   1% of program spending

4. Civica entered into a master service agreement with a us based for profit pharma company on april 18, 2024, to support the global supply of (fill and finish) sterile injectable medications which were on the fda drug shortage list, and for which the partnering company is delaying launches in markets due to production capacity constraints. Pursuant to work orders under this agreement, civica is producing both pre-filled syringes and cartridges for assembly into injection devices. This program advances civica's mission to increase access to essential, affordable medications by supporting a low-cost, reliable production of high-demand, clinically important treatments for patients.

   $385,798 spent$1,623,058 earned by the program
   0% of program spending

The 4 programs described on its FY2024 Form 990, listed largest first by expense. Program spending in total: $87,342,285.